Biogen Buying Rare-Disease Drugmaker in $7.3 Billion Deal
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link